Liu Shuai, Yu Xiaowei, Ye Feifei, Jiang Liangxian
Department of Gastrointestinal Surgery, Taizhou Hospital of Zhejiang Province, Taizhou, China.
Department of Day Care Ward, Taizhou Hospital of Zhejiang Province, Taizhou, China.
Front Surg. 2022 Sep 19;9:971326. doi: 10.3389/fsurg.2022.971326. eCollection 2022.
Inflammatory markers are being increasingly used to predict the prognosis of cancer patients. We hereby conducted the first meta-analysis assessing the association between systemic inflammation score (SIS) and prognosis of gastric cancer patients undergoing surgical intervention.
A literature search was carried out on PubMed, CENTRAL, Scopus, and Embase up to 3rd June 2022 for relevant studies. Adjusted data reported as hazard ratios (HR) was combined in a random-effects model.
A total of seven studies with 5,338 patients could be included. All studies were from either China or Japan and published in the last four years. Meta-analysis showed that higher SIS scores (1 or 2) were significant predictors of poor overall survival (OS) in gastric cancer patients (HR: 1.25 95% CI: 1.05, 1.49, = 11%). Similarly, the meta-analysis demonstrated that an SIS score of 2 was associated with poor OS as compared to scores of 0/1 (HR: 2.53 95% CI: 1.30, 4.89, = 45%). Data on disease-free survival (DFS) was scarce to draw conclusions.
The SIS score can be a simple and useful tool to predict OS in gastric cancer patients undergoing surgery. Data on DFS is scarce and conflicting. Future studies should report using standard reference groups and provide data on DFS to enhance current evidence. https://www.crd.york.ac.uk/prospero/#searchadvanced, identifier: CRD42022335548.
炎症标志物越来越多地用于预测癌症患者的预后。我们在此进行了第一项荟萃分析，评估全身炎症评分（SIS）与接受手术干预的胃癌患者预后之间的关联。
截至2022年6月3日，在PubMed、CENTRAL、Scopus和Embase上进行文献检索以查找相关研究。以风险比（HR）报告的校正数据在随机效应模型中合并。
总共纳入了7项研究，涉及5338名患者。所有研究均来自中国或日本，且在过去四年中发表。荟萃分析表明，较高的SIS评分（1或2）是胃癌患者总生存期（OS）较差的显著预测因素（HR：1.25，95%CI：1.05，1.49，P = 11%）。同样，荟萃分析表明，与0/1分相比，SIS评分为2与较差的总生存期相关（HR：2.53，95%CI：1.30，4.89，P = 45%）。无病生存期（DFS）的数据稀少，无法得出结论。
SIS评分可以作为预测接受手术的胃癌患者总生存期的一种简单且有用的工具。DFS的数据稀少且相互矛盾。未来的研究应报告使用标准参照组并提供DFS数据，以加强现有证据。https://www.crd.york.ac.uk/prospero/#searchadvanced，标识符：CRD42022335548。
